Rituximab, developed in partnership by Roche and Biogen Idec, was the first anti-CD20 monoclonal antibody to be approved for the treatment of non-Hodgkin lymphomas. It works by specifically ...

In the case we report, this dilemma was resolved by successful treatment with rituximab. Rituximab has established benefit for the treatment of lupus and rheumatoid arthritis, for which it is ...

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

Most patients were able to stay with treatment once starting it, with retention rates of about 60% to 80% through 12 months (rituximab had the highest retention and IL-6 inhibitors the lowest).

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

High-efficacy therapy was defined as ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri). At ages 23-27, those who had earlier treatment had less disability, said Sifat Sharmin ...

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

JAK inhibitors were found to be either marginally more effective or as effective as biologic DMARDs in reducing pain in ...

You have treatment in cycles or blocks. Each cycle usually lasts for 28 days ... Or you might have ibrutinib with venetoclax. venetoclax either on its own, or with rituximab, obinutuzumab or ibrutinib ...